A Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

1.81B

+7.63%

1.372

+4.73%

1.76B

+5.76%

1.392

+6.23%

1.83B

+5.11%

1.491

+8.81%

Estimates Revision

The market is revising Upward the revenue expectations for Agilent Technologies, Inc. (A) for FY2026, with the revenue forecasts being adjusted by 1.01% over the past three months. During the same period, the stock price has changed by 6.00%.

Revenue Estimates for FY2026

Revise Upward

+1.01%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-1.23%

In Past 3 Month

Stock Price

Go Up

+6.00%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is 167.92 USD with a low forecast of 130.00 USD and a high forecast of 185.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

130.00

Averages

167.92

High

185.00

Current: 0.000

Low

130.00

Averages

167.92

High

185.00

Evercore ISI

In Line -> Outperform

upgrade

$155 -> $160

2026-01-05

New

Reason

Evercore ISI

Price Target

$155 -> $160

2026-01-05

New

upgrade

In Line -> Outperform

Reason

As previously reported, Evercore ISI upgraded Agilent (A) to Outperform from In Line with a price target of $160, up from $155, upgraded Azenta (AZTA) to Outperform from In Line with a price target of $50, up from $34, upgraded iRhythm (IRTC) to Outperform from In Line with a price target of $210, up from $194, and upgraded Zimmer Biomet (ZBH) to Outperform from In Line with a price target of $120, up from $94, as part of a look-ahead note for the MedTech and Life Science Tools group. Conversely, the analyst downgraded Avantor (AVTR) to In Line from Outperform with a price target of $12, down from $14, downgraded Bausch + Lomb (BLCO) to In Line from Outperform with an unchanged price target of $18, downgraded Exact Sciences (EXAS) to In Line from Outperform with an unchanged price target of $105, downgraded Guardant Health (GH) to In Line from Outperform with a price target of $105, up from $90, downgraded Hologic (HOLX) to In Line from Outperform with a price target of $78, down from $79, and downgraded Bio-Techne (TECH) to In Line from Outperform with a price target of $62, down from $68. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

Evercore ISI

In Line -> Outperform

upgrade

$155 -> $160

2026-01-05

New

Reason

Evercore ISI

Price Target

$155 -> $160

2026-01-05

New

upgrade

In Line -> Outperform

Reason

Evercore ISI upgraded Agilent to Outperform from In Line with a price target of $160, up from $155.

Barclays

Equal Weight -> Overweight

upgrade

$165

2025-12-15

Reason

Barclays

Price Target

$165

2025-12-15

upgrade

Equal Weight -> Overweight

Reason

Barclays upgraded Agilent to Overweight from Equal Weight with an unchanged price target of $165. The firm adjusted ratings in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Goldman Sachs

Buy

initiated

$170

2025-12-09

Reason

Goldman Sachs

Price Target

$170

2025-12-09

initiated

Buy

Reason

Goldman Sachs initiated coverage of Agilent with a Buy rating and $170 price target. The firm rolled out coverage of the large cap life science tools stocks with the expectation that they will eventually return to their historic market growth rate of 5%. However, some end markets will recover faster than others, the analyst tells investors in a research note. Goldman is taking a more cautious view on the timing of the drug discovery end market recovery and believes the recent uptick in biotech funding is largely focused on later stage assets. It also takes a more cautious stance on U.S. academic and government spending. The firm says investors need to be selective, and likes exposure to commercialized biopharma manufacturing, later stage research, and industrials.

Morgan Stanley

initiated

$180

2025-12-02

Reason

Morgan Stanley

Price Target

$180

2025-12-02

initiated

Reason

As previously reported, Morgan Stanley initiated coverage of Agilent (A) with an Overweight rating and $180 price target. Life Science Tools and Diagnostics end market bright spots are beginning to emerge and the firm sees "plenty of catalysts" in the pipeline across its coverage, adding that it sees "lots to like in the space entering 2026." However, a recent industry valuation spike in the second half of the year leaves multiples in "a fair place," so the firm starts the group with an In-Line industry view, the analyst tells investors. Among the group, the analyst identifies Danaher (DHR) as Top Pick. This note corrects a prior version with an incorrect price target for Agilent.

Baird

Catherine Ramsey Schulte

Outperform

maintain

$142 -> $165

2025-11-25

Reason

Baird

Catherine Ramsey Schulte

Price Target

$142 -> $165

2025-11-25

maintain

Outperform

Reason

Baird analyst Catherine Ramsey Schulte raised the firm's price target on Agilent to $165 from $142 and keeps an Outperform rating on the shares. The firm updated its model following solid Q4 results which posted a revenue beat and a 2026 inline revenue outlook.

Valuation Metrics

The current forward P/E ratio for Agilent Technologies Inc (A.N) is 23.19, compared to its 5-year average forward P/E of 25.58. For a more detailed relative valuation and DCF analysis to assess Agilent Technologies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

25.58

Current PE

23.19

Overvalued PE

29.84

Undervalued PE

21.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

20.79

Current EV/EBITDA

19.36

Overvalued EV/EBITDA

23.92

Undervalued EV/EBITDA

17.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.83

Current PS

5.32

Overvalued PS

6.59

Undervalued PS

5.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

A News & Events

Events Timeline

No data

News

8.0

01-07NASDAQ.COM

Coherent Corp (COHR) Sees 16,037 Options Contracts, 41.7% of Average Daily Volume

2.0

01-06CNBC

Amazon Drives Dow to Record High, Approaching 49,000

3.5

01-06CNBC

Nvidia's Next-Gen AI Chips Enter Full Production, Boosting Autonomous and Industrial AI

People Also Watch

Frequently Asked Questions

What is Agilent Technologies Inc (A) stock price today?

The current price of A is 148.52 USD — it has increased 1.89 % in the last trading day.

What is Agilent Technologies Inc (A)'s business?

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.

What is the price predicton of A Stock?

What is Agilent Technologies Inc (A)'s revenue for the last quarter?

Agilent Technologies Inc revenue for the last quarter amounts to 1.86B USD, increased 9.41 % YoY.

What is Agilent Technologies Inc (A)'s earnings per share (EPS) for the last quarter?

Agilent Technologies Inc. EPS for the last quarter amounts to 1.52 USD, increased 23.58 % YoY.

What changes have occurred in the market's expectations for Agilent Technologies Inc (A)'s fundamentals?

How many employees does Agilent Technologies Inc (A). have?

Agilent Technologies Inc (A) has 18100 emplpoyees as of January 10 2026.

What is Agilent Technologies Inc (A) market cap?

Today A has the market capitalization of 42.11B USD.